Today: 12 June 2026
Browse Category

NYSE:LLY 26 December 2025 - 5 January 2026

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly shares dropped 3.4% to $1,043.14 after Novo Nordisk launched U.S. sales of an oral Wegovy weight-loss pill starting at $149 a month. Novo’s move intensified focus on pricing in the obesity drug market. The Health Care Select Sector SPDR ETF fell 1.3%, while Novo Nordisk shares rose 2.9%. Investors are awaiting Lilly’s next earnings update on February 4.
5 January 2026
···
Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

Healthcare Stocks Today: XLV edges up as drugmakers raise U.S. list prices on 350 medicines

U.S. drugmakers are raising list prices on at least 350 branded medicines for 2026, with a median increase of about 4%, Reuters reported. The Health Care Select Sector SPDR Fund (XLV) closed up 0.46% at $155.51 Friday. Pfizer, Eli Lilly, and Johnson & Johnson all posted gains. Traders are watching next week’s U.S. jobs data and upcoming healthcare earnings.
3 January 2026
····
Eli Lilly stock today: LLY ticks higher as drug-price resets and a fresh upgrade sharpen focus

Eli Lilly stock today: LLY ticks higher as drug-price resets and a fresh upgrade sharpen focus

Eli Lilly shares closed up 0.53% at $1,080.36 Friday, then slipped 0.17% after hours. Drug pricing remains in focus as list-price resets and Medicare negotiations begin the year. Zacks upgraded Lilly to “strong-buy” and Reuters reported a 40% list-price cut for Jardiance. CEO David Ricks will speak at the J.P. Morgan Healthcare Conference on January 13.
3 January 2026
··
Eli Lilly stock (LLY) edges higher after hours today as drug-pricing reset and January catalysts loom

Eli Lilly stock (LLY) edges higher after hours today as drug-pricing reset and January catalysts loom

Eli Lilly shares rose 0.5% to $1,080.36 in after-hours trading Friday after a volatile session. The move follows sector-wide drug price changes and renewed Washington scrutiny, with manufacturers planning 2026 list-price hikes. Investors are watching upcoming U.S. jobs and inflation data, as well as Lilly’s Jan. 13 conference appearance ahead of its Feb. 4 earnings report.
3 January 2026
··
Eli Lilly stock forecast 2026: Analysts see modest upside as pricing pressure bites

Eli Lilly stock forecast 2026: Analysts see modest upside as pricing pressure bites

Drugmakers plan to raise U.S. list prices on at least 350 branded medicines in 2026, with a median increase of about 4%, according to 3 Axis Advisors. List prices for about nine drugs will drop, including a more than 40% cut for Jardiance after Medicare negotiations. Eli Lilly faces price pressure in both the U.S. and China, where its diabetes drug Mounjaro will also get cheaper from Jan. 1.
1 January 2026
··
Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

Eli Lilly shares slipped 0.1% to $1,078.95 by early afternoon Wednesday after reports of price cuts for its diabetes and obesity drugs in China and a planned U.S. list-price reset. A regulatory filing showed Lilly Endowment, the company’s largest shareholder, trimmed its stake slightly. Investors focused on pricing pressure as the company’s GLP-1 drugs face broader access and lower prices heading into 2026.
31 December 2025
···
Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers Health shares fell 0.5% to $32.87 in premarket trading Wednesday after closing down 3.1% the previous session. The move follows price cuts by Novo Nordisk and Eli Lilly on obesity drugs in China, raising questions about future margins and demand for GLP-1 therapies. Hims recently launched its weight-loss membership in the UK, offering access to Wegovy and Mounjaro.
31 December 2025
····
Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

Eli Lilly shares edged up 0.1% after hours to $1,079.75 following news it and Novo Nordisk are cutting prices on top obesity drugs in China. Novo confirmed Wegovy price reductions; a hospital WeChat post showed Mounjaro’s 10mg pen dropping to 445 yuan ($63) from 2,180 yuan. Novo’s U.S. shares slipped about 0.5%. Lilly Endowment Inc. disclosed selling 3,593 shares in a regulatory filing.
30 December 2025
···
Eli Lilly stock today: LLY inches up as weight-loss pill pricing, insider filing keep spotlight on obesity drugs

Eli Lilly stock today: LLY inches up as weight-loss pill pricing, insider filing keep spotlight on obesity drugs

Eli Lilly shares rose 0.2% to $1,078.73 in after-hours trading Monday, with 1.64 million shares traded. Lilly Endowment Inc. disclosed the sale of 2,629 shares at $1,085.17 each, retaining over 92 million shares. Investors focused on obesity drug pricing, with Lilly and Novo Nordisk preparing pill versions and shifting to telehealth and direct-to-consumer sales. The S&P 500 fell 0.35% and the Nasdaq lost 0.5%.
29 December 2025
··
Eli Lilly stock steadies into Monday as $55 million ABL Bio funding keeps pipeline in focus

Eli Lilly stock steadies into Monday as $55 million ABL Bio funding keeps pipeline in focus

Eli Lilly shares closed at $1,077.75, up $0.55, after ABL Bio announced it will receive $40 million upfront and a $15 million equity investment from Lilly under a research deal. The agreement follows a broader pact valued at up to $2.6 billion. Investors are watching for 2026 regulatory decisions on Lilly’s obesity drug pipeline. The S&P 500 and Dow slipped slightly on Friday.
29 December 2025
··
Eli Lilly Stock (LLY) News Today: What Investors Should Watch Before Monday’s Open After GLP‑1 Pill Breakthroughs, Pricing Signals, and Fresh Deal Headlines

Eli Lilly Stock (LLY) News Today: What Investors Should Watch Before Monday’s Open After GLP‑1 Pill Breakthroughs, Pricing Signals, and Fresh Deal Headlines

Eli Lilly shares closed at $1,077.75 Friday, near record highs, as U.S. markets shut for the weekend. ABL Bio announced $55 million in new funding tied to Lilly, including a $40 million upfront payment and $15 million equity investment. Investors remain focused on obesity-drug momentum and the FDA’s recent approval of Novo Nordisk’s weight-loss pill.
28 December 2025
·
Eli Lilly Stock (LLY) Outlook for Monday: Latest Deal Headlines, GLP-1 Pill Race, and Wall Street Targets

Eli Lilly Stock (LLY) Outlook for Monday: Latest Deal Headlines, GLP-1 Pill Race, and Wall Street Targets

Eli Lilly shares closed near record highs Friday at $1,077.75, with trading volume muted ahead of the weekend. ABL Bio announced it expects a $40 million upfront payment and $15 million equity investment from Lilly tied to their Grabody platform collaboration. The deal targets obesity and muscle diseases. Novo Nordisk’s oral Wegovy approval this week intensified competition in the obesity drug market.
28 December 2025
··
Eli Lilly Stock (LLY) Update: Latest Price, Fresh Headlines, Analyst Forecasts, and What to Watch Before Markets Reopen

Eli Lilly Stock (LLY) Update: Latest Price, Fresh Headlines, Analyst Forecasts, and What to Watch Before Markets Reopen

Eli Lilly shares ended Friday at $1,077.75, near record highs, as the market weighed strong demand for obesity drugs against rising pricing and access pressures. Novo Nordisk’s FDA approval for an oral Wegovy pill this week put pressure on Lilly, whose own oral therapy is expected in 2026. The stock’s equity value remains around $1 trillion. U.S. markets reopen Monday, with traders watching for weekend developments.
27 December 2025
·
Eli Lilly Stock (LLY) Holds Near $1,078 After Friday’s Close as GLP‑1 Pricing, Pill Competition, and Retatrutide Data Shape the 2026 Outlook

Eli Lilly Stock (LLY) Holds Near $1,078 After Friday’s Close as GLP‑1 Pricing, Pill Competition, and Retatrutide Data Shape the 2026 Outlook

Eli Lilly shares closed Friday near $1,077.75, little changed after a narrow session. The Centers for Medicare & Medicaid Services this week announced a plan to expand GLP‑1 drug access, capping monthly costs at $50 for Medicare beneficiaries. A Trump-era pricing deal also sets lower reference prices for weight-loss drugs. Investors are watching policy shifts as key drivers for LLY’s valuation.
27 December 2025
··
Eli Lilly Stock (LLY) Today: GLP‑1 Price Cuts, the Obesity Pill Race, and What Investors Are Watching Into 2026

Eli Lilly Stock (LLY) Today: GLP‑1 Price Cuts, the Obesity Pill Race, and What Investors Are Watching Into 2026

Eli Lilly shares traded near $1,075 Friday afternoon, down 0.2% in thin post-Christmas trading as U.S. indexes hovered close to record highs. The stock moved between $1,068 and $1,082 amid muted volume. The NYSE and Nasdaq remained open for a regular session. Investors continue to watch Lilly’s pricing moves and its lead in obesity and diabetes treatments.
26 December 2025
··
1 … 5 6 7 8 9 … 13

Stock Market Today

  • USDA Boosts Argentina Soybean Production, Weighing on Soybean Prices
    June 12, 2026, 8:43 AM EDT. Soybeans fell modestly on Thursday, with cash prices down 7 3/4 cents to $10.61 1/2 amid an increase in Argentina's production forecast by the U.S. Department of Agriculture (USDA). The USDA raised Argentina's soybean output by 2 million metric tons (MMT) to 50 MMT, contributing to a global supply surplus and higher world ending stocks for 2025/26. U.S. export sales for soybeans declined 23.7% week-on-week but remained above last year's levels. Soymeal futures showed mixed results, while soy oil futures dropped. Brazil's production was steady at 180 MMT. The USDA's World Agricultural Supply and Demand Estimates (WASDE) report signaled stable U.S. old and new crop stocks, with a slight internal adjustment. Market participants are adjusting to the increased international supplies amid ongoing trade demand.

Latest articles

Richtech Robotics Stock Drops After Restatement Warning

Richtech Robotics Stock Drops After Restatement Warning

12 June 2026
Richtech Robotics plunged up to 10% premarket after disclosing that audited financial statements for 2024, 2025, and multiple quarters should not be relied upon, citing errors tied to warrant liabilities, a SEPA, and restricted stock awards; investors now await amended filings and Nasdaq compliance updates as valuation remains uncertain.
National Grid Shares Slip After UK Grid Reform; £70bn Plan in Spotlight

National Grid Shares Slip After UK Grid Reform; £70bn Plan in Spotlight

12 June 2026
National Grid shares slipped 0.41% to 1,203p, underperforming the FTSE 100, as investors weighed the impact of UK grid-connection reforms that boost long-term investment prospects but increase execution risk; next catalysts are the July AGM/dividend vote and November half-year results, with analysts’ median 12-month target at 1,388.5p, about 15% above current levels.
Go toTop